1 published article · Updated continuously
10 trials tracked for Erythropoietic Protoporphyria: 5 in phase 3 or 4 and 3 with published results. The most-cited published study has 280 citations.
Showing the 10 most-cited and recently-updated of 10 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Afamelanotide has been evaluated in multiple Phase 3 trials for the management of phototoxicity in Erythropoietic Protoporphyria. Evidence indicates that Afamelanotide is associated with significant increases in the duration of direct sunlight exposure on pain-free days (10:00 to 15:00) compared to placebo [2, 7]. Furthermore, some studies reported substantial gains in sun tolerance during the 10:00 to 18:00 window 3.
Clinical data from Afamelanotide trials also demonstrate a reduction in the cumulative number of days with phototoxic reactions 5. Patients treated with Afamelanotide showed significant improvements in Quality of Life scores (SF36 Physical Component) compared to those on placebo [3, 5]. Additionally, Colestipol has been evaluated for its effect on photosensitivity, showing a recorded sun tolerance of 65.8 minutes 6.
AI synthesis of 4 cited trials, updated Jun 23, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
